Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 45.04 USD -0.53%
Market Cap: 3.7B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Verona Pharma PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Verona Pharma PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Verona Pharma PLC
NASDAQ:VRNA
Additional Paid In Capital
$621.6m
CAGR 3-Years
18%
CAGR 5-Years
34%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Additional Paid In Capital
ÂŁ3.5B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Additional Paid In Capital
$35.2B
CAGR 3-Years
64%
CAGR 5-Years
35%
CAGR 10-Years
24%
Indivior PLC
LSE:INDV
Additional Paid In Capital
$11m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Additional Paid In Capital
$282m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Dechra Pharmaceuticals PLC
LSE:DPH
Additional Paid In Capital
ÂŁ596m
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
17%
No Stocks Found

Verona Pharma PLC
Glance View

Market Cap
3.7B USD
Industry
Pharmaceuticals

Verona Pharma PLC, an ambitious player in the biopharmaceutical arena, is woven into the intricate tapestry of the healthcare industry, focusing its energies on respiratory ailments. Born within the thriving biopharma sector in London, this company has targeted chronic obstructive pulmonary disease (COPD) with its novel therapies, driven by the urgent need to alleviate this global burden. The company's flagship product, ensifentrine, serves as a dual inhibitor of the enzymes phosphodiesterase 3 and 4, aiming to enhance lung function and ease the constriction challenges faced by patients. Through strategic clinical trials and robust scientific inquiry, Verona Pharma seeks not only to innovate in treatment but also to deliver tangible hope for those grappling with chronic respiratory conditions. Verona Pharma's business model is anchored in advancing its drug development pipeline, propelled by a blend of scientific rigor and strategic partnerships. It capitalizes on patent protection and licensing agreements to secure its financial footing, investing heavily in research to drive value creation. The company earns its revenue predominantly from collaborative agreements with larger pharmaceutical entities, milestone payments, and potential royalties upon successful commercialization of its therapies. Through aligning with other industry giants, Verona Pharma not only financially fortifies its pursuits but also accelerates the dissemination of its therapeutic innovations, ensuring that their beneficial impacts reach as many patients as possible. This harmonized approach with partners places Verona Pharma on a trajectory not just of financial growth but also of achieving its underlying mission – transforming the landscape of respiratory disease management.

VRNA Intrinsic Value
14.59 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Verona Pharma PLC's Additional Paid In Capital?
Additional Paid In Capital
621.6m USD

Based on the financial report for Sep 30, 2024, Verona Pharma PLC's Additional Paid In Capital amounts to 621.6m USD.

What is Verona Pharma PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
34%

Over the last year, the Additional Paid In Capital growth was 3%. The average annual Additional Paid In Capital growth rates for Verona Pharma PLC have been 18% over the past three years , 34% over the past five years .

Back to Top